Applicant, as named in the Orange Book

Heron Theraps Inc

Next listed expiry: Aponvie on 18 Sep 2035. 3 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Aponvie NDA 216457 aprepitant	aprepitant	18 Sep 2035 patent	patent
Cinvanti NDA 209296 aprepitant	aprepitant	18 Sep 2035 patent	patent
Zynrelef Kit NDA 211988 · 2 strengths bupivacaine; meloxicam	bupivacaine; meloxicam	21 Apr 2036 patent, carve-out possible	patent, carve-out possible

Zynrelef Kit · Exclusivity expires within 90 days I-933Exclusivity expires 23 Jan 2027Detected 25 Oct 2026
Zynrelef Kit · Exclusivity expires within 90 days I-933Exclusivity expires 23 Jan 2027Detected 25 Oct 2026
Zynrelef Kit · Exclusivity expires within 90 days I-933Exclusivity expires 23 Jan 2027Detected 25 Oct 2026
Zynrelef Kit · Exclusivity expires within 90 days I-933Exclusivity expires 23 Jan 2027Detected 25 Oct 2026
Aponvie · First generic approved · ANDA 218851, MylanApproved 5 Mar 2026Detected 25 Oct 2026
Aponvie · Generic approved · ANDA 218851, MylanApproved 5 Mar 2026Detected 25 Oct 2026